Indaptus amends ATM agreement to supersede 2022 pact
Indaptus Therapeutics amended its at-market sales agreement with H.C. Wainwright & Co. for future common stock offerings, replacing its previous nearly four-year-old agreement.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day